Predictive Oncology Inc.(POAI)Earnings, Financials & Key Ratios
POAI•NASDAQ
$4.91
Price updated Jun 20, 2026
AboutPredictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Show more
- Revenue$2M-0.2%
- EBITDA-$10M+13.7%
- Net Income-$12M+12.7%
- EPS (Diluted)-2.24+35.6%
- Gross Margin49.12%-21.5%
- EBITDA Margin-630.85%+13.5%
- Operating Margin-673.69%+9.5%
- Net Margin-751.39%+12.5%
- ROE-302.42%-224.8%
POAI Price & Volume
Predictive Oncology Inc. (POAI) stock price & volume — 10-year historical chart
Loading chart...
Predictive Oncology Faces Severe Operational Liquidity Crisis
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
"Predictive Oncology is currently navigating an existential financial crisis characterized by a 99% year-over-year revenue contraction and a negative gross margin of -131%. The company's inability to maintain its commercial footprint across its core segments has resulted in a deep equity deficit of -$77.4M, rendering the current business model unsustainable. Investors should exercise extreme caution as the firm's cash reserves have dwindled to $181.7K, leaving the company with a current ratio of 0.01 and minimal path toward operational solvency."
Verdict Logic
the company's current cash position of $181.7K against a history of consistent operating losses suggests an imminent risk of liquidity exhaustion.
POAI Growth Metrics
Predictive Oncology Inc. (POAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.49%
5 Years2.84%
3 Years4.56%
TTM-47.2%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-503.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3436.58%
Return on Capital
10 Years-247.91%
5 Years-153.72%
3 Years-114.39%
Last Year-184.71%
Peers Comparison
Key metrics vs top competitors for Predictive Oncology Inc. (POAI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.91 | $26.78M | -2.19 | -0.24% | -751.39% | -302.42% | — | |
| $3.52 | $1.57B | -2.44 | 26.92% | -844.46% | -54.32% | — | |
| $10.89 | $1.7B | -12.96 | -38.24% | -6450.76% | -63.58% | — | |
| $16.86 | $1.26B | -11.96 | 23.29% | -40.6% | -30.85% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $28.82 | $1.49B | -72.05 | 13.79% | -1.98% | -2.61% | — |
Compare POAI vs Peers
Predictive Oncology Inc. (POAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when POAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
POAI Frequently Asked Questions
Predictive Oncology Inc. (POAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Predictive Oncology Inc.'s revenue?
Predictive Oncology Inc. (POAI) reported $0.7M in revenue for fiscal year 2024.
How fast is Predictive Oncology Inc. growing?
Predictive Oncology Inc. (POAI) saw revenue decline by 0.2% over the past year.
Is POAI profitable?
Predictive Oncology Inc. (POAI) reported a net loss of $84.3M for fiscal year 2024.
Dividend & Returns
What is POAI's return on equity?
Predictive Oncology Inc. (POAI) has a return on equity (ROE) of -302.4%. Negative ROE indicates the company is unprofitable.
What is Predictive Oncology Inc.'s free cash flow?
Predictive Oncology Inc. (POAI) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.